Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Ramm Pharma ( (TSE:RAMM) ).
RAMM Pharma Corp. has announced additional details regarding its proposed investment in Global South S.A.S, a private Uruguayan company. The transaction involves a US$5 million investment for a 10% equity stake, with an option to increase ownership to 25%. This strategic move requires minority shareholder approval due to related party considerations, as Global South is owned by RAMM’s CEO. The company plans to raise necessary funds through asset monetization or financing, aiming to complete the transaction within nine months, although timing is uncertain.
Spark’s Take on TSE:RAMM Stock
According to Spark, TipRanks’ AI Analyst, TSE:RAMM is a Neutral.
Ramm Pharma’s overall stock score is primarily impacted by its poor financial performance, characterized by significant losses and cash flow challenges. While technical analysis shows some positive momentum, the high volatility and potential overbought conditions pose risks. The negative P/E ratio and lack of dividend yield further weaken the stock’s valuation.
To see Spark’s full report on TSE:RAMM stock, click here.
More about Ramm Pharma
RAMM Pharma Corp. operates in the pharmaceutical industry, focusing on cannabis-derived products and related services. The company is involved in strategic investments to enhance its market position.
Average Trading Volume: 104,948
Technical Sentiment Signal: Hold
Current Market Cap: C$1.79M
See more data about RAMM stock on TipRanks’ Stock Analysis page.